News & Publications

News Releases

April 22, 2025
FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors
Read More
January 7, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors
Read More
December 5, 2023
Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors
Read More

Publications

January 7, 2025
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Nature Medicine
Read More

For press inquiries, please contact:

Barbara Yates
781-258-6153
barbara@theyatesnetwork.com